Compare ARK Genomic Revolution ETF (ARKG) vs Allbirds Inc (BIRD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Allbirds Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Allbirds Inc trades at $3.11 (market cap $27.52M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BIRD | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $16.99 |
52-Week Low | $23.09 | $2.39 |
Market Cap | — | $27.52M |
Enterprise Value | — | $46.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BIRD (Smartbird) trades at $3.13, down 9.54% today, reflecting volatility following its pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with mixed oscillators, while fundamentals reveal persistent losses: revenue declined to $152.47M in 2025 with a net margin of -53.36%. Recent news highlights the company's rebranding and new CEO appointment, driving significant stock movements amid investor speculation on its AI strategy.
The outlook is highly speculative, with opportunity stemming from potential AI business execution, but substantial risks remain due to negative profitability, cash burn, and reliance on a unproven new direction. Analyst consensus is cautious, with 78.57% hold ratings, indicating skepticism about near-term turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
